Latest news

• Biogen’s R&D chief Ehlers heads for the exit

  The departure comes after a difficult few months in which Biogen has pulled the plug on two of its amyloid-targeting Alzheimer’s disease programmes –  aducanumab and elenbecestat – after disappointing efficacy

• Biogen loses another pipeline drug to toxicity concerns

  Follows discontinuation of Eisai-partnered Alzheimer's drug. Just a few days after calling time on its Eisai-partnered Alzheimer’s drug  elenbecestat, Biogen has another pipeline casualty – this time its

• Biogen and Eisai drop Alzheimer’s drug elenbecestat

  Latest blow in string of failures for BACE inhibitor category. In a potential final blow to the BACE inhibitor treatment category, Biogen and Eisai have discontinued trials of elenbecestat after the ... The failure of elenbecestat comes on the heels

• Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms

  The loss of CNP520 leaves just one major BACE inhibitor standing – Eisai and Biogen’s elenbecestat.

• Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022

  The additional study could also include an arm combining BAN2401 with Eisai’s BACE inhibitor elenbecestat, a drug class that has also seen a string of failures in late-stage testing ... Meanwhile, Eisai says in an update published today that it is